Introduction
shown clinical efficacy in a subset of patients with advanced cancers (10) (11) (12) . However, many cancer patients do not respond to anti-PD-1 and anti-Tim-3 therapy (13, 14) . Although the combination of anti-PD-1 and anti-Tim-3 therapies has shown additive effects in preclinical animal models, unmet needs in combination therapy targeting in cancer patients remain (14) .
It has long been thought that the antitumor effect of checkpoint inhibitors is attributed to the reinvigoration of cytotoxic T cells (CTLs), although most MHC class I-deficient tumor cells readily escape immunosurveillance by the CTLs (3) . Considering that NK cells also co-express PD-1 and Tim-3 in MHC class I-deficient tumor-bearing mice with tumor progression, NK cells have emerged as another target for checkpoint blockade immunotherapy (6) .
Cytokine therapies have been tested in preclinical studies and clinical trials to treat cancer by directly activating immune cells, including T cells (4, 15) . Because NK cells express receptors for various cytokines, including IL2, IL7, IL12, IL15, IL18, and IL21, the addition of these cytokines also promotes the activation and maturation of NK cells (4, 16, 17) . For example, we previously demonstrated that the administration of IL21 in MHC class I-deficient tumor-bearing mice induced robust antitumor immunity through the reactivation of exhausted NK cells (5) . Although many cytokine therapies have shown promising clinical outcomes in cancer patients, potential toxicity at higher doses has been a hurdle to their clinical application (18) (19) (20) . Therefore, the development of strategies for minimizing the adverse effect of cytokine therapy while maintaining its efficacy is required.
In the present study, we found that PD-1 and Tim-3 blockade restrained MHC class I- 
Materials and Methods

Mice and human samples
Female C57BL/6 mice were purchased from Charles River Laboratories (Orient, Seoul, Korea).
All mice were used at 6 to 10 weeks of age and were bred and maintained in the specific pathogen-free vivarium of the Seoul National University. All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at Seoul National University. The human tumor tissue and normal tissue specimens from patients with colorectal (n=3), melanoma (n=1), and bladder cancer (n=1) were obtained from surgical specimens of patients. The matched normal tissues were at least 2 cm away from the edge of corresponding tumors. The tumor tissues were placed in in RPMI 1640 medium (GIBCO) that was supplemented with 10% FBS (GIBCO), 1% penicillin/streptomycin (Lonza), 1 mM sodium pyruvate (Lonza), 0.1 mM N.E.A.A. (Lonza), 55 mM 2-mercaptoethanol (GIBCO), and 25 mM HEPES (Lonza) on ice before the tumor dissociation. Tumor tissues less than 1 cm were excluded from this study. The collection of human samples was approved by the ethical committee of Severance Hospital.
Reagents and antibodies
The antibodies for flow cytometry were purchased from Biolegend (San Diego, CA, USA), eBioscience (San Diego, CA, USA), and BD Biosciences (San Jose, CA, USA and pRGEN-Cas9-CMV using Lipofectamine 2000 (Invitrogen)), according to the manufacturer's protocol. Each genome-edited cell line was sorted by a T7E1 assay (Toolgen, Seoul, Korea) with single-cell selection or FACSARIA III (BD Bioscience). For T7E1 assay with single-cell selection, we followed the manufacturer's protocol. For sorting with FACS ARIA III, we sorted the negative population after staining with knockout molecules in tumor cells. For verifying the purity of knockout tumor cell lines, we analyzed the expression of knockout molecules using FACS ARIAIII (BD Bioscience) after stimulation for 24h with mouse IFNγ (10 ng/mL; R&D systems) to induce knockout of molecules.
For primary cell culture (primary cells were lymphocytes taken from mouse/human tumor tissue), the mouse primary cells were cultured in RPMI 1640 (GIBCO) medium that was supplemented with 10% FBS (GIBCO) and 1% penicillin-streptomycin (Lonza). Human primary cells were cultured in X-VIVO15 medium (Lonza) that was supplemented with 1% penicillin-streptomycin (Lonza). For NK cell culture, a low dose (1~2 ng/mL) of rIL2 was added to the culture medium for cell survival. All cell lines were found to be negative for mycoplasma contamination, and these cell lines were used at passage 3 to 7 for all experiments after MHC class I-deficient cell lines generation.
In vitro cytotoxicity assay
The NK cells were prepared from tumor-infiltrating lymphocytes from MHC class I-deficient, ).
Quantification of chemokine production by tumor cells
To measure the production of the CCL5, CXCL9, and CXCL10 chemokines by tumor cells, 
Statistics.
Statistical comparisons were performed using the Prism (version 6.0) software (GraphPad Fig. S2 ). PD-L1 deficiency almost completely abrogated the progression of MHC class I-deficient tumor cells, whereas the tumor progression was partially inhibited by galectin-9 deficiency (Fig. 1B) , and PD-L1 or galectin-9 deficiency increased intratumoral NK cell cytotoxicity against mice bearing each type of tumor (Fig. 1C) . The frequencies of IFNγ + and granzyme B (GrazB) + NK cells were inversely correlated with tumor burdens, suggesting that both PD-1/PD-L1 and Tim-3/gal-9 axes contribute to the functional exhaustion of tumor-infiltrating NK cells in MHC class I-deficient tumor-bearing mice (Fig. 1D ).
We next sought to examine whether the abrogation of either PD-1/PD-L1 or Tim-3/galectin-9 signaling by anti-PD-1 or anti-Tim-3 treatment, respectively, could inhibit the progression of MHC class I-deficient tumor cells. Our previous study revealed that Tim-3 expression on NK cells was induced a few days earlier than PD-1 expression. Based on this finding, anti-Tim-3 treatment started earlier than anti-PD-1 treatment, and to exclude the possible involvement of CD8 + T cells in response to checkpoint blockade, CD8 + T cells were depleted using anti-CD8 ( Fig. 2A) . We found that anti-PD-1 or anti-Tim-3 treatment inhibited tumor growth and improved survival compared with control IgG treatment (median survival:
32 days), and anti-PD-1 treatment inhibited tumor growth and improved the survival of the tumor-bearing mice (median survival: 46.50 days) to a greater extent than treatment with antiTim-3 (median survival: 36 days) ( Fig. 2B and C) . We then tested whether a combination of anti-PD-1 and anti-Tim-3 could induce an additive increase in the antitumor effects against 
MHC class I-deficient tumors. Although tumor growth was not significantly inhibited by the combination therapy, the addition of an anti-Tim-3 antibody marginally extended the survival of the mice compared with the anti-PD-1 antibody alone (Fig. 2B and C) . (Fig. 3A and B) . The addition of exogenous rIL21 further increased IFNγ and granzyme B expression in tumor-infiltrating NK cells isolated from mice treated with anti-PD-1/anti-Tim-3 ( Fig. 3A and B) . Collectively, these results suggest that the combination of rIL-21 and anti-PD-1/anti-Tim-3 may foster antitumor immune responses against MHC class Ideficient tumors by enhancing the effector function of exhausted NK cells.
Combination IL21 and checkpoint blockade enhances antitumor effects
To evaluate whether checkpoint blockade could further enhance IL21-mediated 
antitumor immunity against MHC class I-deficient tumors, intratumoral rIL21 in combination with anti-PD-1/anti-Tim-3 was administered to M1 KO MC38, TC-1, and CT26 tumor-bearing mice. To exclude the possible involvement of CD8 + T cells in response to either IL21 or checkpoint blockade, CD8 + T cells were depleted using anti-CD8 (Fig. 4A, Supplementary Fig.   S2A and S4A). Although both intratumoral rIL21 alone and anti-PD-1/anti-Tim-3 alone were comparably effective for restraining M1 KO MC38 and TC-1 tumor growth compared with control IgG, a combination of rIL21 and anti-PD-1/anti-Tim-3 therapies was more effective than each monotherapy in terms of tumor progression, as well as survival of the mice ( Fig. 4B and C, Supplementary Fig. S4B and C). However, although intratumoral rIL21 and anti-PD-1/anti-Tim-3 alone were comparably effective for restraining M1 KO CT26 tumor growth compared with control IgG, the combination therapy was not more effective than each monotherapy in terms of tumor progression in mice bearing CT26 tumors ( Supplementary Fig.   S4D ).
The frequency of IFNγ + intratumoral NK cells was significantly increased after the combination of rIL21 and anti-PD-1/anti-Tim-3 therapies, suggesting that combination therapy additively restored the function of exhausted NK cells ( Fig. 4D and Supplementary Fig.   S4C ). In contrast, the frequency and absolute number of intratumoral NK cells were significantly increased by the combination therapy but were indistinguishable from those with the rIL21 treatment alone, indicating that IL21 was responsible for the recruitment of NK cells into the tumor site ( Supplementary Fig. S5 ). The antitumor effect of combination therapy was dependent on NK cells, as NK cell depletion by anti-NK1.1 treatment abrogated the tumor growth inhibition by combination therapy (Fig. 4E ).
To verify whether the combination of rIL21 with checkpoint blockade enhances antitumor effects in MHC class I-deficient tumors, we administered checkpoint blockade alone, Fig. S6A ). Although both intratumoral rIL21 alone and anti-PD-1 alone were comparably effective for restraining M1&Gal9 KO MC38 tumor growth compared with control IgG, the combination of rIL21 with anti-PD-1 was more effective than each monotherapy in terms of tumor progression ( Supplementary Fig. S6B ), and although antiTim-3 alone or intratumoral rIL21 alone did not significantly inhibit M1&PD-L1 KO MC38 tumor growth compared with control IgG, the combination of rIL21 with anti-Tim-3 significantly suppressed M1&PD-L1 KO MC38 tumor growth ( Supplementary Fig. S6C ).
Collectively, these results suggest that IL21 and anti-PD-1/anti-Tim-3 combination therapy improves antitumor immunity by enhancing tumor infiltration and the effector function of NK cells.
Increased local accumulation of NK cells by intratumoral administration of rIL21
As we described earlier, we found that the combination of rIL21 and checkpoint blockade therapies or rIL21 alone increased the tumor infiltration of NK cells (Supplementary Fig. S5 ).
It is possible that intratumoral administration of rIL21 increases the recruitment of NK cells to the tumor site. To address this possibility, rIL21 was administered intratumorally in MHC class I-deficient tumor-bearing mice. After 3 administrations of rIL21, the frequency and absolute number of tumor-infiltrating NK cells were significantly increased compared with the vehicle treatment ( Fig. 5 A and B) . CXCR3 expression on tumor-infiltrating NK cells and CXCL9 and CXCL10 production by MC38 and TC-1 tumor cells were significantly enhanced by rIL21 treatment, suggesting that CXCR3-dependent chemotaxis is associated with the increased recruitment of NK cells at the tumor site by rIL21 (Fig. 5C-E and Supplementary Fig S7A and   B) . However, CCL5 production by each tumor cell was not significantly enhanced by rIL21 treatment ( Fig. 5F and Supplementary Fig. S7C ). Consistent with this notion, CXCR3 blockade abrogated the IL21-mediated increase in NK cell infiltration at the tumor site (Fig. 5G-I ) and completely abolished the tumor growth inhibition by rIL21 treatment (Fig. 5J) PD-1 and Tim-3 expressed on exhausted T cells are well known targets for cancer immunotherapy, and various ongoing clinical trials are targeting these molecules (11, 33, 34) .
Several studies have shown that PD-1 and Tim-3 expression on NK cells results in deceased cytokine production, degranulation and cytotoxicity, indicating that these co-inhibitory molecules not only act on T cells but also on NK cells (6) (7) (8) (9) 24) . In our previous study, we also show that PD-1 Another study has demonstrated that PD-1 expression of tumor-associated macrophages (TAMs) gradually increase over time in tumor-bearing mice and in cancer patients with increasing disease stages (42, 43) . These authors also show that PD-1/PD-L1 blockade inhibits tumor growth in various mouse tumor models by enhancing the phagocytosis of TAMs (42, 43) . Another study shows that the intratumoral delivery of IL21 can skew TAM 
polarization from the M2 phenotype to the M1 phenotype, which is known to inhibit tumor progression (44) (18, 19) . However, our combination regimen of rIL21 and checkpoint blockade did not induce any evident side effects, such as weight loss.
Considering that rIL21 has been proven safe in clinical trials for treating metastatic melanoma patients or renal cell carcinoma patients, rIL21 might be one of the most promising candidates as a combination partner for checkpoint blockade immunotherapy (49, 50) . Although rIL21 was intratumorally injected in the present study to avoid possible systemic detrimental effects of 
